On August 19th, Gelunhui reported that Shanghai Medicilon Inc. (stock code: 688202.SH) released its semi-annual report. In the first half of 2024, the company's new signed orders and revenue both declined year-on-year, with revenue of 0.521 billion yuan, a YoY decrease of 40.23%. During the reporting period, the company's customer structure was mainly domestic customers, with domestic customer revenue of 0.331 billion yuan, accounting for 63.66% of the main business revenue; overseas customer revenue was 0.189 billion yuan, accounting for 36.34% of the main business revenue; net loss was 70.23 million yuan, turning losses year-on-year.
During the reporting period, the net income attributable to shareholders of the listed company and the net income deducting non-recurring profits and losses attributable to shareholders of the listed company both declined by 142.27% and 150.98%, respectively. This is mainly due to intensified competition in the pharmaceutical industry during the reporting period, a decline in order prices, and delays in the execution of some orders, leading to a decrease in revenue and profit.
